2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Src
  5. Src Isoform

Src

 

Src Related Products (117):

Cat. No. Product Name Effect Purity
  • HY-10234
    Saracatinib
    		Inhibitor 99.92%
    Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases.
  • HY-10158
    Bosutinib
    		Inhibitor 99.96%
    Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
  • HY-13805
    PP2
    		Inhibitor 99.35%
    PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC50s of 4 and 5 nM for Lck and Fyn, respectively.
  • HY-12299
    WH-4-023
    		Inhibitor 99.75%
    WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC50 of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and VEGFR2/KDR/Flk-1.
  • HY-13024
    Rebastinib
    		Inhibitor 99.91%
    Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, VEGFR2/KDR/Flk-1, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
  • HY-161687
    Cisplatin/Dasatinib prodrug-1
    		Inhibitor
    Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC50s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively.
  • HY-P10665
    pYEEI
    		Inhibitor
    pYEEI is a phosphotyrosine-containing tetrapeptide binds to Src SH2 domain with the Kd of 100 nM and with the IC50 of 6.5 μM. pYEEI plays an important role in cancer research.
  • HY-101447
    SI-2
    		Inhibitor
    SI-2 (EPH 116) is an inhibitor for steroid receptor coactivator-3 (SRC-3), which reduces the transcriptional activity and protein concentration of SRC-3 in cells, exhibits cytotoxicity in cancer cell, with IC50s ranging from 3-20 nM, inhibits migration of MDA-MB-468, induces apoptosis of MDA-MB-468. SI-2 inhibits the tumor growth in mouse models, without significant toxicity for heart and other major organs (20 mg/kg).
  • HY-10209
    Masitinib
    		Inhibitor 99.98%
    Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity.
  • HY-10340
    Tirbanibulin
    		Inhibitor 99.56%
    Tirbanibulin (KX2-391) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
  • HY-50868
    Bafetinib
    		Inhibitor 99.77%
    Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph+ leukemia cells. Bafetinib has antitumor activity.
  • HY-B0789
    SU6656
    		Inhibitor 98.05%
    SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.
  • HY-12072
    Lck Inhibitor
    		Inhibitor 99.45%
    Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC50s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis.
  • HY-112096
    eCF506
    		Inhibitor 99.77%
    eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase Src with an IC50 of less than 0.5 nM.
  • HY-N0752
    Scutellarein
    		Inhibitor 99.25%
    Scutellarein is a natural flavonoid compound with anti-inflammatory effects.
  • HY-15764A
    A 419259 trihydrochloride
    		Inhibitor 99.21%
    A 419259 trihydrochloride is a Src family kinases inhibitor with IC50s of 9 nM, 3 nM and 3 nM for Src, Lck and Lyn, respectively.
  • HY-101053
    Src Inhibitor 1
    		Inhibitor 99.96%
    Src Inhibitor 1 is a potent, ATP-competitive and selective dual site Src tyrosine kinase inhibitor with IC50 values of 44 nM for Src and 88nM for Lck.
  • HY-59047
    Tolimidone
    		Activator 99.93%
    Tolimidone is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM.
  • HY-13942
    1-NM-PP1
    		Inhibitor 99.17%
    1-NM-PP1, a cell-permeable PP1 analog, is a potent Src family kinases inhibitor with IC50s of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively.
  • HY-13804
    PP1
    		Inhibitor 99.00%
    PP1 is a potent, and Src family-selective tyrosine kinase inhibitor with IC50 of 5 and 6 nM for Lck and Fyn, respectively.